MMA and the creation of the Medicare Part D prescription benefit has many pharmaceutical executives on edge. The sudden proliferation of new managed care players, new partnerships and alliances, and new products, such as PDPs and regional PPOs, makes it difficult for pharmaceutical companies to know exactly who their biggest managed markets customers are. In fact, PBMs – once considered the 500-pound gorilla in terms of negotiating formulary placement, pricing, and rebates – are not necessarily always the biggest kid on the block in the new, evolving, Medicare managed care market.

That is why more pharmaceutical executives are turning to the Gorman Health Group for help in sorting out what’s happening in the managed care market, who the big players are, and how this market is likely to evolve in the coming years. Our team of well-respected thought leaders have spoken at dozens of pharmaceutical executive conferences, and given numerous lectures and training seminars to pharmaceutical staff and their key customer segments around the country. In addition, our consultants have worked with pharmaceutical companies to generate models to structure, market, price, and administer their key prescription products to their managed markets customers.

Gorman Health Group encourages pharmaceutical companies that may be struggling to understand what to do in the new Medicare environment to contact us and tell us what your specific needs and challenges are. We’ll be happy to customize our offerings to help you position yourself as effectively as possible with your managed markets clients.

For more information, please contact Carol Sardinha at 202 364-8283